Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Blumenfeld

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Neurology|November 17, 2022
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Headache|April 5, 2021
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction studyAbhijeet Jakate, Andrew M Blumenfeld, Ramesh Boinpally, et al.
Pain and Therapy|February 12, 2026
Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Chronic Migraine and Concomitant Therapeutic IndicationsAndrew M Blumenfeld, Christopher Rhyne, Kenneth Martinez, et al.
Headache|February 3, 2016
Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based SurveyAndrew Messali, Joanna C Sanderson, Andrew M Blumenfeld, et al.
Headache|January 18, 2023
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trialMessoud Ashina, Stewart J Tepper, Uwe Reuter, et al.
Cephalalgia : an International Journal of Headache|October 15, 2025
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trialPatricia Pozo-Rosich, Andrew M Blumenfeld, Richard B Lipton, et al.
Headache|December 15, 2025
OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trialAndrew M Blumenfeld, Larry Charleston, Deena Kuruvilla, et al.
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
Headache|March 6, 2013
Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)Andrew M Blumenfeld, Lisa M Bloudek, Werner J Becker, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
Headache-related health resource utilisation in chronic and episodic migraine across six countriesJoanna C Sanderson, Emily B Devine, Richard B Lipton, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Neurology|November 17, 2022
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Headache|April 5, 2021
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction studyAbhijeet Jakate, Andrew M Blumenfeld, Ramesh Boinpally, et al.
Pain and Therapy|February 12, 2026
Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Chronic Migraine and Concomitant Therapeutic IndicationsAndrew M Blumenfeld, Christopher Rhyne, Kenneth Martinez, et al.
Headache|February 3, 2016
Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based SurveyAndrew Messali, Joanna C Sanderson, Andrew M Blumenfeld, et al.
Headache|January 18, 2023
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trialMessoud Ashina, Stewart J Tepper, Uwe Reuter, et al.
Cephalalgia : an International Journal of Headache|October 15, 2025
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trialPatricia Pozo-Rosich, Andrew M Blumenfeld, Richard B Lipton, et al.
Headache|December 15, 2025
OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trialAndrew M Blumenfeld, Larry Charleston, Deena Kuruvilla, et al.
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
Headache|March 6, 2013
Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)Andrew M Blumenfeld, Lisa M Bloudek, Werner J Becker, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
Headache-related health resource utilisation in chronic and episodic migraine across six countriesJoanna C Sanderson, Emily B Devine, Richard B Lipton, et al.
Pageof 5